Danaher (DHR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Q3 performance and macro environment

• Q3 results exceeded expectations, with strong performance in Cepheid and bioprocessing; life sciences and diagnostics met expectations.

• Underlying drivers from Q3 are continuing into Q4, supporting ongoing momentum.

• Manufacturing in China primarily serves the local market, minimizing exposure to tariffs; supply chain is regionally structured.

• Less than 1% of business is tied to NIH funding, and less than 5% to academic and research globally.

• No short-term impact seen from leadership changes at HHS, FDA, or CMS; pharma customers remain confident.

M&A and capital deployment

• M&A environment remains uncertain due to conflicting regulatory signals, but balance sheet strength positions for opportunities.

• High market multiples favor focus on smaller, bolt-on deals over large transactions.

Bioprocessing and biopharma trends

• Bioprocessing shows gradual recovery, with five consecutive quarters of sequential order growth and high single-digit growth in Q3.

• Large customers (75%) have normalized ordering; smaller customers (20-25%) show improvement but with more disciplined spending.

• Book-to-bill metric is less emphasized; focus is on order backlog and velocity, with Q4 being critical for 2025 visibility.

• End markets, especially for monoclonal antibodies, support high single-digit to low double-digit growth.

• China bioprocessing remains at low activity due to funding constraints and regulatory changes; sequential improvement seen but no short-term catalysts.

• Equipment/capital is 15-20% of bioprocessing, growing slower than consumables but showing sequential growth among large customers.